Ipsen's 5% quarterly sales increase boosted by Somatuline

French drugmaker Ipsen (Euronext: IPN) reported growth in sales in the third quarter of 2015 due to its Somatuline’s (lanreotide) turnover increasing 33.7% year-on-year.

Consolidated group sales grew 5.2% at constant currency to 354.5 million euros ($387.5 million), driven by the performance of specialty care.

Marc de Garidel, chairman and chief executive of Ipsen, said: “Specialty care remains our main growth driver thanks to the successful launch of Somatuline in neuroendocrine tumors in the USA and Europe and the growth of Dysport (abobotuliniumtoxinA), notably in the aesthetic indication. Moreover, the challenging environment in emerging markets, especially in China, is still adversely affecting the performance of Decapeptyl (triptorelin) and of the primary care.”